PMV PHARMACEUTICALS INC's ticker is PMVP and the CUSIP is 69353Y103. A total of 112 filers reported holding PMV PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.62 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,085,936 | +3.9% | 339,729 | +5.9% | 0.00% | – |
| Q2 2023 | $2,008,196 | +36.5% | 320,798 | +4.0% | 0.00% | – |
| Q1 2023 | $1,471,574 | -47.3% | 308,506 | -3.8% | 0.00% | -100.0% |
| Q4 2022 | $2,790,377 | -25.9% | 320,733 | +1.3% | 0.00% | 0.0% |
| Q3 2022 | $3,767,000 | -15.6% | 316,518 | +1.1% | 0.00% | 0.0% |
| Q2 2022 | $4,462,000 | -12.8% | 313,137 | +27.4% | 0.00% | 0.0% |
| Q1 2022 | $5,116,000 | -11.2% | 245,758 | -1.4% | 0.00% | 0.0% |
| Q4 2021 | $5,759,000 | -23.6% | 249,293 | -1.5% | 0.00% | 0.0% |
| Q3 2021 | $7,541,000 | -14.9% | 253,076 | -2.5% | 0.00% | -50.0% |
| Q2 2021 | $8,866,000 | +66.6% | 259,515 | +60.4% | 0.00% | +100.0% |
| Q1 2021 | $5,323,000 | -44.6% | 161,827 | +3.6% | 0.00% | -50.0% |
| Q4 2020 | $9,612,000 | +1595.2% | 156,278 | +878.1% | 0.00% | – |
| Q3 2020 | $567,000 | – | 15,978 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Euclidean Capital LLC | 4,179,416 | $257,076,000 | 54.42% |
| INTERWEST VENTURE MANAGEMENT CO | 6,469,911 | $397,964,000 | 49.71% |
| Octagon Capital Advisors LP | 250,000 | $15,378,000 | 5.33% |
| Boxer Capital, LLC | 2,268,236 | $139,519,000 | 4.48% |
| COMMODORE CAPITAL LP | 125,000 | $7,689,000 | 4.18% |
| Orbimed Advisors | 7,330,423 | $450,894,000 | 3.95% |
| Asymmetry Capital Management, L.P. | 96,595 | $5,942,000 | 2.71% |
| Avoro Capital Advisors LLC | 2,350,267 | $130,536,000 | 2.25% |
| RA Capital Management | 1,710,265 | $105,198,000 | 1.47% |
| HighVista Strategies LLC | 22,654 | $1,393,000 | 0.89% |